Description
Uses of Pazopanib (Votrient) Medicine:
Pazopanib is a kinase inhibitor primarily used for treating adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS), particularly in patients who have already undergone chemotherapy. This drug works by inhibiting specific proteins in cancer cells, which helps slow down or stop their growth.
However, the efficacy of Pazopanib for treating specific types of soft tissue sarcomas, like adipocytic soft tissue sarcoma and gastrointestinal stromal tumors (GIST), has not been established. This means it may not be as effective for those particular cancer types, and alternative treatments may be considered.
Dosage & Side Effects:
The recommended dosage of Pazopanib is 800 mg (four 200 mg tablets) orally once daily without food (at least 60 minutes before or 2 hours after a meal) until there is evidence of disease progression or unacceptable toxicity. The dosage should be modified for hepatic impairment and in patients taking certain concomitant medicines.
Swallow tablets whole. avoid crushing them due to the potential for an increased rate of absorption, which may affect systemic exposure. If a dose of Pazopanib is missed, it should not be taken if it is < 12 hours until the next scheduled dose.
The most common side effects of Pazopanib 400 mg/200 mg tablets in patients with renal cell carcinoma (RCC) (occurring in ≥ 20% of patients) are vomiting, diarrhea, hypertension, nausea, hair color changes, and anorexia. In patients with soft tissue sarcoma (STS) (occurring in ≥ 20% of patients), the side effects are diarrhea, fatigue, nausea, decreased weight, musculoskeletal pain, hypertension, hair color changes, decreased appetite, tumor pain, vomiting, dyspnea, headache, dysgeusia, and skin hypopigmentation.